VRE rate, highest in BRA and MEX; all inhibited by TIG and daptomycin, but not LZD (three non-susceptible with G2576T mutations or cfr). Penicillin-R among SPN and viridans streptococci was 51.6 and 41.1%, respectively. LZD overall R against Gram-positives was 0.3%.
Introduction
Recent escalations of ␤-lactamase-mediated resistances (extended-spectrum ␤-lactams [ESBL], serine carbapenamases [KPCs] , OXA-series Class D enzymes, and metallo-␤-lactamases [MBL] ) worldwide has complicated antimicrobial therapy of important/common Gram-negative bacillary infections. [1] [2] [3] [4] Already existing resistance challenges among Gram-positive cocci (methicillin-resistant staphylococci, vancomycin-resistant enterococci [VRE] and multidrug-resistant [MDR] pneumococci) further emphasize the needs for global, regional, national and local surveillance of antimicrobial susceptibility patterns to guide empiric therapy and direct or monitor interventions. [5] [6] [7] These resistant strains increase patient morbidity and mortality, as well as the cost of medical care delivery. 4, 7 Current surveillance programs, particularly at the global level, [1] [2] [3] have concentrated on larger economically developed nations where fiscal markets and supporting regulatory agencies (USA-FDA, EMA) would recognize the value, and have the resources to sustain monitoring. In contrast, surveillance data from countries outside the major markets having faced more limited support for drug resistance monitoring, drug patent protection, prescription drug law and antimicrobial stewardship programs are more limited. 4 Beginning in 2011, the Latin American (LATAM) surveillance programs (SENTRY Antimicrobial Surveillance Program and several others) administered by JMI Laboratories (North Liberty, Iowa, USA) were expanded to include sites within some countries having limited sampling support or not having significant reported statistics. This regional resistance surveillance program provides reference susceptibility test information in several areas of the world including 11 countries in LATAM including seven that are uncommonly sampled (Colombia, Costa Rica, Ecuador, Guatemala, Panama, Peru and Venezuela). Data from testing nearly 5000 clinical isolates in 2011 are presented here.
Materials and methods

Nations and organisms sampled
Eleven countries in LATAM (20 laboratory sampling sites having 93-503 organism samples/site) were sampled with a target of ≥250 isolates per nation. These institutions were generally tertiary-care hospitals. The compliance to protocol ranged from 190 [Venezuela, 95%] to >100% for the "developed" countries. The collected organisms were isolated consecutively from various types of clinical infections (prevalence design) including bloodstream (18.8%), respiratory tract (20.1%), skin and skin structure (13 Tables 2 and 3 ; the remaining organisms occurred in small numbers precluding a significant sample size per species, e.g. limited analytical power.
Organisms detected with resistances to key, available agents were tested by various molecular methods such as PCR amplification/sequencing, example ESBLs, MBLs, MDR Gramnegative bacilli or Gram-positive cocci. 1, 2 Methods and antimicrobials tested CLSI M07-A9 (2012) methods were applied using validated broth microdilution panels produced by ThermoFisher Scientific Inc., formerly TREK Diagnostics (Cleveland, Ohio, USA). 8 Interpretations of results utilized CLSI (M100-S23, 2013), USAFood and Drug Administration (FDA) and EUCAST (2013) criteria; 9-11 and the results of quality control (QC) tests were dominantly (nearly 99.0%) within QC ranges (CLSI M100-S23) for six utilized control organisms. S. pneumoniae (182) isolates from LATAM were dominantly penicillin-non-susceptible (51.6%; using CLSI non-meningitis breakpoints) with highest rates observed in Mexico (84.8%) and Venezuela (81.2%). Similarly, ceftriaxone non-susceptible rates were elevated (21.1-43.7%) in the same two nations. Poor coverage (low susceptible %) were noted for erythromycin (62.6%), tetracycline (63.7-64.8%) and TMP/SMX (45.1-48.4%). The best antimicrobials tested against pneumococci were levofloxacin, linezolid, tigecycline and vancomycin, each inhibiting all strains at published breakpoints (Table 2 ). For other streptococci, important resistance profiles observed were: (1) 13.9 and 56.5% non-susceptible for macrolides and tetracyclines in ␤-haemolytic streptococci, respectively, (2) ≥91.1% susceptible rates for all drugs except penicillin (58.9%, CLSI criteria), erythromycin (50.0%) and tetracycline (61.1%) in viridans group streptococci, and (3) rare daptomycin (1.1%) and fluoroquinolone non-susceptible (1.7-3.3%) rates were observed (Table 2) . Tables 3 and 4 E. coli (644) had an ESBL-phenotype rate of 37.3%, see Table 4 . The most active tested agents were amikacin (92.7% susceptible), cefoperazone/sulbactam (92.7%), meropenem (100.0%) and tigecycline (100.0%). The most active cephalosporin against E. coli was cefepime at 72.4% by CLSI breakpoints (Table 3) . Klebsiella spp. (517) showed very elevated resistance rates ( Table 3 .
Results and discussion
Antimicrobial profiles of Gram-negative bacilli are found in
P. aeruginosa (586) were most susceptible to amikacin (75.4%), tobramycin (70.1%) and colistin (99.5%; Table 3 ). Carbapenem resistance was high due to endemic ␤-lactamase (SPM-1, usually in Brazil), but the most elevated rates were noted in Guatemala (75.8%), Peru (62.5-68.8%) and Ecuador (55.6%). The most active ␤-lactam was ceftazidime (65.7%, MIC 50 at 4 mg/L). Acinetobacter spp. (494, four species) were significantly inhibited (% susceptible) only by colistin (98.6%), cefoperazone/sulbactam (59.3%), doxycycline (80.4%) and tigecycline (MIC 90 , 4 mg/L). All carbapenems, aminoglycosides and ampicillin/sulbactam showed susceptibility rates at <50%, many <20%; see Table 3 .
Monitoring of nearly 5000 LATAM pathogens in 2011 documents increasing antimicrobial resistances among nearly all sampled species (Tables 1-3) , confirming earlier reports. 1, 3, 6 Although methicillin resistance was elevated among staphylococci (47.8-83.9%), several agents (daptomycin, glycopeptides, linezolid and tigecycline) retained potent activity in LATAM like elsewhere in the world. 4 -7 VRE appears to be expanding (14.2-15.1%, in 10 nations) as are non-susceptible rates for ␤-lactams in S. pneumoniae. In contrast, USA rates of VRE particularly among bacteremia isolates of E. faecium have escalated to more than 80%, 12 and ceftriaxone non-susceptible rates were at 12.5% in 2009 samples of pneumococci. 13 Rare linezolid-resistant (<1.0% overall) CoNS and enterococci were noted with cfr and target site mutations, as previously noted in Mexico. 6 ␤-Lactamase-mediated (ESBL, MBL [NDM-1], Class A and D carbapenamases) resistance in E. coli, Klebsiella spp., some other Enterobacteriaceae, and non-fermentative bacilli continues to evolve (Table 3) to levels of 37.3-52.4% and few drugs have ≥90.0% level inhibition at published breakpoints. [1] [2] [3] [4] 14 This demands routine use of combination empiric therapies directed by surveillance programs and patient isolate tests for LATAM patients; and interventions will be required to control further resistance escalation in this geographic region.
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